Strengthening IP enforcement - Next Generation Labs announces complete assignment of South Korean TFN® R-S Nicotine Manufacturing Patent to NextEra

Share Article

Under the Next Generation Labs assignment, NextEra products containing TFN® will continue to be sold, and NextEra will use all means available to protect the market and prohibit violative brands from entering South Korea.

TFN

This is a strategic patent assignment that will give NextEra the full freedom to use all legal means at its disposal to seek enforcement of existing intellectual property rights related to TFN® recreational nicotine in the market.

Next Generation Labs LLC, the world’s largest manufacturer of TFN® R-S, S and R isomer nicotine has fully assigned the rights of its Republic of Korea R-S Nicotine Manufacturing Patent (# 10-1855611) to NextEra Co., Inc. (“NextEra”).

Next Generation Labs “has taken this step to help strengthen direct in-market enforcement efforts by NextEra against unscrupulous manufacturers who have attempted to ship unauthorized synthetic, non-synthetic, and in some instances, counterfeit or mislabeled TFN® synthetic nicotine vape products into the South Korea market.”

NextEra is Next Generation Labs’ exclusive TFN® partner and is the largest flavor formulator and distributor of synthetic nicotine vape products in South Korea. Under the assignment, NextEra products containing TFN® will continue to be sold, and NextEra will use all means available to protect the market and prohibit violative brands from entering South Korea.

Next Generation Labs added, “this is a strategic patent assignment that will give NextEra the full freedom to use all legal means at its disposal to seek enforcement of existing intellectual property rights related for TFN® recreational nicotine in the market.”

With full control of this patent, “Next Generation Labs fully expects NextEra to immediately take action against violators, and utilize all necessary legal remedies against any business seeking to either: divert R-S nicotine product sales into South Korea from other markets, attempt to sell mislabeled tobacco-derived nicotine as a synthetic product, or to sell counterfeit TFN® products in South Korea.”

The terms of the patent transaction have not been made public, and the transaction will not impact Next Generation Labs other patents in South Korea, or impact control of patents in any other jurisdiction worldwide.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sales and Marketing

NGL Public Relations

+1 973 668 3887
Email >
Visit website